Headlines about Pfizer (NYSE:PFE) have been trending somewhat positive this week, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than 6,000 news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfizer earned a media sentiment score of 1.00 on their scale. InfoTrie also gave news coverage about the biopharmaceutical company an news buzz score of 1 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have effected Pfizer’s analysis:
- Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC – Business Wire (businesswire.com)
- Pfizer urges noteholders to reject offer by Huguenot Bond Liquidity (seekingalpha.com)
- Pfizer, Ranbaxy Sued Over Delay Of Generic Lipitor – Law360 (law360.com)
- Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC – Olean Times Herald (oleantimesherald.com)
Shares of PFE stock traded up $0.24 during trading on Friday, reaching $37.50. 14,885,114 shares of the company’s stock were exchanged, compared to its average volume of 22,354,300. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $206.97 billion, a PE ratio of 13.39, a PEG ratio of 2.72 and a beta of 0.71. Pfizer has a twelve month low of $27.88 and a twelve month high of $44.56. The firm’s fifty day moving average price is $36.51 and its 200-day moving average price is $36.84.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 8th will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date of this dividend is Thursday, May 7th. Pfizer’s payout ratio is presently 51.53%.
A number of brokerages recently issued reports on PFE. Morgan Stanley dropped their target price on Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 2nd. Standpoint Research raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, February 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price target on shares of Pfizer in a research report on Thursday, March 19th. Royal Bank of Canada reaffirmed a “buy” rating and set a $44.00 price target on shares of Pfizer in a research report on Monday, April 27th. Finally, Barclays boosted their price target on Pfizer from $36.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $41.28.
In related news, SVP Jennifer B. Damico sold 2,181 shares of the business’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $38.35, for a total value of $83,641.35. Following the completion of the sale, the senior vice president now directly owns 9,647 shares in the company, valued at approximately $369,962.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pfizer Inc purchased 312,500 shares of Pfizer stock in a transaction that occurred on Monday, March 16th. The stock was purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. Insiders own 0.08% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.